Recent Analysts’ Ratings Changes for Natera (NTRA)

A number of research firms have changed their ratings and price targets for Natera (NASDAQ: NTRA):

• 11/6/2024 – Natera was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/30/2024 – Natera had its price target raised by analysts at Sanford C. Bernstein from $125.00 to $135.00. They now have an “outperform” rating on the stock.
• 10/29/2024 – Natera had its price target raised by analysts at Canaccord Genuity Group Inc. from $145.00 to $150.00. They now have a “buy” rating on the stock.
• 10/25/2024 – Natera was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/17/2024 – Natera had its price target raised by analysts at Leerink Partners from $140.00 to $150.00. They now have an “outperform” rating on the stock.
• 10/17/2024 – Natera was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/16/2024 – Natera had its price target raised by analysts at The Goldman Sachs Group, Inc. from $125.00 to $140.00. They now have a “buy” rating on the stock.
• 9/13/2024 – Natera had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $150.00 price target on the stock.

Natera Stock Performance

NTRA stock traded up $2.58 on Wednesday, reaching $126.97. The company’s stock had a trading volume of 1,149,263 shares, compared to its average volume of 1,308,358. Natera, Inc. has a 52 week low of $40.61 and a 52 week high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The company has a market capitalization of $15.70 billion, a P/E ratio of -51.82 and a beta of 1.53. The firm has a fifty day moving average of $123.59 and a two-hundred day moving average of $113.06.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. During the same quarter in the previous year, the business earned ($0.97) EPS. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. As a group, analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Jonathan Sheena sold 12,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now owns 287,441 shares of the company’s stock, valued at approximately $34,783,235.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53. Following the completion of the sale, the chief executive officer now directly owns 200,710 shares in the company, valued at approximately $23,866,426.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 12,000 shares of the company’s stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $121.01, for a total value of $1,452,120.00. Following the completion of the transaction, the insider now directly owns 287,441 shares in the company, valued at approximately $34,783,235.41. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,164 shares of company stock worth $6,157,291. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Natera

Several hedge funds have recently bought and sold shares of NTRA. Covestor Ltd boosted its holdings in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. GAMMA Investing LLC boosted its stake in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the period. CIBC Asset Management Inc increased its position in Natera by 3.3% in the 3rd quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after buying an additional 111 shares during the period. Moss Adams Wealth Advisors LLC lifted its holdings in shares of Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after buying an additional 135 shares during the last quarter. Finally, Private Advisor Group LLC boosted its position in shares of Natera by 5.2% in the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock valued at $346,000 after acquiring an additional 135 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.